Abivax S.A.
ABVXNASDAQHealthcareBiotechnology
Previous close
$114.95
−$3.245 · -2.75%
ABVX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
31
Expensive
Momentum
65
Gaining
Sentiment
55
Mixed
Risk resilience
65
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAbivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- FR
- CEO
- Marc de Garidel
- Listed since
- Oct 20, 2023
- Employees
- 80
Market position
Day range
Current $114.95
52-week range
Current $114.95
- Open
- $117.69
- Previous close
- $118.2
- Volume
- 988.64K
- 0.58× average
- Average volume
- 1.7M
- Average daily volume
- Market cap
- 8.44B USD
- Beta
- -0.23
- Market reference 1
- 50-day average
- $121.83
- -5.65% below average
- 200-day average
- $118.95
- -3.36% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 7.51B EUR
- P/E (TTM)
- -21.08×
- P/B (TTM)
- 15.55×
- P/S (TTM)
- 0×
- EV / EBITDA
- -24.97×
- Earnings yield
- -4.21%
- Free cash flow yield
- -1.95%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -73.87%
- Return on assets
- -57.54%
- Return on invested capital
- -44.70%
Financial health
- Debt / equity
- 0.1×
- Current ratio
- 8.75×
Financial statements
Income trends
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 50.76M EUR | 45.52M EUR |
| Gross profit | — | — | — | −50.76M EUR | −45.52M EUR |
| Research and development | 177.76M EUR | 146.53M EUR | 103.18M EUR | 48.3M EUR | 47.78M EUR |
| Selling, general, and administrative | 72.87M EUR | 38.9M EUR | 28.82M EUR | 7.49M EUR | 5.58M EUR |
| Operating expenses | 246.06M EUR | 172.98M EUR | 127.38M EUR | 14.07M EUR | −4.12M EUR |
| Interest income | 5.75M EUR | 8.96M EUR | 2.77M EUR | — | — |
| Interest expense | 28.48M EUR | 12.43M EUR | 13.83M EUR | 6.94M EUR | 3.56M EUR |
| Depreciation and amortization | 1.07M EUR | 1.1M EUR | 707K EUR | 485K EUR | 302K EUR |
| Operating income | −246.06M EUR | −172.98M EUR | −127.38M EUR | −64.84M EUR | −41.4M EUR |
| Net income | −336.1M EUR | −176.24M EUR | −147.74M EUR | −60.74M EUR | −42.45M EUR |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 40%
- 4 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -63.19%
- 10 comparable reports
- Latest EPS result
- -0.71
- Estimate -1.07 · Beat by 33.64%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$152.71
32.85% upsideRating distribution
13 ratingsRecent analyst actions
ABVX news
ABVX peers
ETFs holding ABVX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB57.3M0.54%10.75B USD0.44%$213.56+1.29%
Schwab International Equity ETFSCHF20.01M0.03%69.7B USD0.03%$28.46+0.85%
Goldman Sachs Hedge Industry VIP ETFGVIP13.18M2.08%571.67M USD0.45%$172.92-0.24%
State Street SPDR Portfolio Developed World ex-US ETFSPDW7.12M0.02%41.92B USD0.03%$52.02+0.79%
Alger 35 ETFATFV6.15M1.64%257.79M USD0.56%$39.47+0.58%
Vanguard Total International Stock ETFVXUS3.54M0.00%646.2B USD0.05%$87.71+0.78%
Vanguard FTSE Developed Markets ETFVEA2.35M0.00%315B USD0.03%$73.42+0.80%
Fidelity Nasdaq Composite Index ETFONEQ1.74M0.02%10.35B USD0.21%$103.14+0.41%iShares Biotechnology ETFIBB- Market value
- 57.3M
- Weight
- 0.54%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Schwab International Equity ETFSCHF- Market value
- 20.01M
- Weight
- 0.03%
- AUM
- 69.7B USD
- Expense ratio
- 0.03%
- Price / 1D
- $28.46+0.85%
Goldman Sachs Hedge Industry VIP ETFGVIP- Market value
- 13.18M
- Weight
- 2.08%
- AUM
- 571.67M USD
- Expense ratio
- 0.45%
- Price / 1D
- $172.92-0.24%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 7.12M
- Weight
- 0.02%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
Alger 35 ETFATFV- Market value
- 6.15M
- Weight
- 1.64%
- AUM
- 257.79M USD
- Expense ratio
- 0.56%
- Price / 1D
- $39.47+0.58%
Vanguard Total International Stock ETFVXUS- Market value
- 3.54M
- Weight
- 0.00%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.71+0.78%
Vanguard FTSE Developed Markets ETFVEA- Market value
- 2.35M
- Weight
- 0.00%
- AUM
- 315B USD
- Expense ratio
- 0.03%
- Price / 1D
- $73.42+0.80%
Fidelity Nasdaq Composite Index ETFONEQ- Market value
- 1.74M
- Weight
- 0.02%
- AUM
- 10.35B USD
- Expense ratio
- 0.21%
- Price / 1D
- $103.14+0.41%
Continue in GoAI
Research ABVXresearch.disclaimer